Conference Highlights
Iman Ahmed, PharmD, BCOP, recently discussed the evidence for what’s actually contributing to health inequities in hematologic malignancies, and how providers can mitigate these disparities. Read More ›
Achieving cancer health equity requires combined structural reforms and individual-level support, along with sustained, collaborative commitment. Read More ›
Nurses and navigators, especially those embedded in community programs, can help bridge the access gap by promoting education, building trust, and facilitating access early in the patient journey. Read More ›
Immune checkpoint inhibitors have altered the management of several cancers, including a subset of colorectal cancers characterized by deficient mismatch repair and microsatellite instability. Read More ›
The use of circulating tumor DNA is emerging as a powerful tool in colorectal cancer management, but its potential to address disparities in care remains an ongoing challenge. Read More ›
In 2024, the FDA approved 50 new treatments, highlighting significant advancements in medicine. In addition, that same year ASCO received 7025 abstracts for its scientific program, reflecting an unprecedented pace of innovation and discovery. Read More ›
Despite advances in first-line treatment, long-term prognosis for advanced non–small cell lung cancer (NSCLC) remains poor. Read More ›
Officials with GenFleet Therapeutics announced phase 2 data from the KROCUS study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cetuximab for first-line non–small cell lung cancer (NSCLC) treatment in a late-breaking abstract at the mini oral presentation of the 2025 European Lung Cancer Congress. Read More ›
Updated results from the phase 2 KRYSTAL-7 study continue to highlight the potential of first-line adagrasib (Krazati; Bristol Myers Squibb) combined with pembrolizumab (Keytruda; Merck) in patients with advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) tumor proportion score of ≥50%. Read More ›
Study results presented at the European Lung Cancer Congress 2025 demonstrate the role of osimertinib (Tagrisso; AstraZeneca), as monotherapy across stages and settings of EGFR-mutated non–small cell lung cancer. Read More ›